Castle Biosciences (NASDAQ: CSTL)
Castle Biosciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Castle Biosciences Company Info
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
News & Analysis
Why Castle Biosciences Stock Is Jumping Today
The genetic-testing company beat expectations with its Q2 results.
Why Shares of Castle Biosciences Fell This Week
Insider selling by upper management sent the stock down for a fourth consecutive day.
Why Castle Biosciences Stock Is Crushing It Today
The company received some unexpected good news.
Why Shares of Castle Biosciences Plummeted on Monday
Analysts downgraded their price target for the medical diagnostics stock.
Why Shares of Castle Biosciences Slumped This Week
Investors were unimpressed by the company's study regarding its IDgenetix test.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.